Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

Locally Advanced Prostate Cancer Clinical Trial

Official title:
A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex® (Bicalutamide) Alone or the Combination of Casodex® & ZD1839 (Iressa™)

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00319787
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 2
Start date	December 2003
Completion date	August 2006

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05590793` - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate	Phase 3
Active, not recruiting	`NCT03350529` - MRI Guided Transurethral HIFU for Various Prostate Diseases	N/A
Recruiting	`NCT05406999` - Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer	Phase 2
Not yet recruiting	`NCT06130995` - Relugolix + Enzalutamide Study in High-Risk Prostate Cancer	Phase 1
Recruiting	`NCT06387056` - Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)	Phase 2
Recruiting	`NCT01048151` - TNFerade Biologic to Treat Locally Advanced Prostate Cancer	Phase 1